Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Abstract The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-p...

Full description

Bibliographic Details
Main Authors: Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor, Prasanth Abraham, Jonathan E. Rosenberg
Format: Article
Language:English
Published: BMJ Publishing Group 2017-08-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Bladder cancer
Immunotherapy
Guidelines
Consensus statement
Online Access:http://link.springer.com/article/10.1186/s40425-017-0271-0

Internet

http://link.springer.com/article/10.1186/s40425-017-0271-0

Similar Items